Cytomegalovirus infection and disease after liver transplantation - An overview

Robert J. Stratta, Mark S. Shaeffer, Rodney S. Markin, R. Patrick Wood, Alan N. Langnas, Elizabeth C. Reed, Jeremiah P. Donovan, Gail L. Woods, Kathleen A. Bradshaw, Todd J. Pillen, Byers W. Shaw

Research output: Contribution to journalReview article

84 Citations (Scopus)

Abstract

Cytomegalovirus is the single most important pathogen in clinical transplantation. Although much progress has been made in our understanding of the molecular biology and epidemiology of CMV infection and in our ability to diagnosis and treat CMV disease, it remains a major cause of morbidity but is no longer a major cause of mortality after liver transplantation. Risk factors for CMV disease after liver transplantation include donor and recipient serologic status, the use of antilymphocyte therapy, and retransplantation. CMV disease occurs early after transplantation, and the most frequent site of disease is the hepatic allograft. We have treated 79 patients with intravenous ganciclovir, with ultimate control of disease achieved in 69 patients (87.3%). Preliminary results using intravenous immunoglobulin and oral acyclovir for CMV prophylaxis in high-risk patients have been encouraging. In addition to producing clinical syndromes, CMV may have direct immunologic effects and is a marker of the net state of immunosuppression.

Original languageEnglish (US)
Pages (from-to)673-688
Number of pages16
JournalDigestive Diseases and Sciences
Volume37
Issue number5
DOIs
StatePublished - May 1 1992

Fingerprint

Cytomegalovirus Infections
Liver Transplantation
Transplantation
Ganciclovir
Molecular Epidemiology
Acyclovir
Intravenous Immunoglobulins
Cytomegalovirus
Immunosuppression
Allografts
Molecular Biology
Tissue Donors
Morbidity
Mortality
Liver
Infection

Keywords

  • OKT3
  • acyclovir
  • cytomegalovirus
  • ganciclovir
  • immunoglobulin
  • immunosuppression
  • liver transplantation

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Cytomegalovirus infection and disease after liver transplantation - An overview. / Stratta, Robert J.; Shaeffer, Mark S.; Markin, Rodney S.; Wood, R. Patrick; Langnas, Alan N.; Reed, Elizabeth C.; Donovan, Jeremiah P.; Woods, Gail L.; Bradshaw, Kathleen A.; Pillen, Todd J.; Shaw, Byers W.

In: Digestive Diseases and Sciences, Vol. 37, No. 5, 01.05.1992, p. 673-688.

Research output: Contribution to journalReview article

Stratta, RJ, Shaeffer, MS, Markin, RS, Wood, RP, Langnas, AN, Reed, EC, Donovan, JP, Woods, GL, Bradshaw, KA, Pillen, TJ & Shaw, BW 1992, 'Cytomegalovirus infection and disease after liver transplantation - An overview', Digestive Diseases and Sciences, vol. 37, no. 5, pp. 673-688. https://doi.org/10.1007/BF01296422
Stratta, Robert J. ; Shaeffer, Mark S. ; Markin, Rodney S. ; Wood, R. Patrick ; Langnas, Alan N. ; Reed, Elizabeth C. ; Donovan, Jeremiah P. ; Woods, Gail L. ; Bradshaw, Kathleen A. ; Pillen, Todd J. ; Shaw, Byers W. / Cytomegalovirus infection and disease after liver transplantation - An overview. In: Digestive Diseases and Sciences. 1992 ; Vol. 37, No. 5. pp. 673-688.
@article{ff8bf4fcdbb7473e8308279879cd22b2,
title = "Cytomegalovirus infection and disease after liver transplantation - An overview",
abstract = "Cytomegalovirus is the single most important pathogen in clinical transplantation. Although much progress has been made in our understanding of the molecular biology and epidemiology of CMV infection and in our ability to diagnosis and treat CMV disease, it remains a major cause of morbidity but is no longer a major cause of mortality after liver transplantation. Risk factors for CMV disease after liver transplantation include donor and recipient serologic status, the use of antilymphocyte therapy, and retransplantation. CMV disease occurs early after transplantation, and the most frequent site of disease is the hepatic allograft. We have treated 79 patients with intravenous ganciclovir, with ultimate control of disease achieved in 69 patients (87.3{\%}). Preliminary results using intravenous immunoglobulin and oral acyclovir for CMV prophylaxis in high-risk patients have been encouraging. In addition to producing clinical syndromes, CMV may have direct immunologic effects and is a marker of the net state of immunosuppression.",
keywords = "OKT3, acyclovir, cytomegalovirus, ganciclovir, immunoglobulin, immunosuppression, liver transplantation",
author = "Stratta, {Robert J.} and Shaeffer, {Mark S.} and Markin, {Rodney S.} and Wood, {R. Patrick} and Langnas, {Alan N.} and Reed, {Elizabeth C.} and Donovan, {Jeremiah P.} and Woods, {Gail L.} and Bradshaw, {Kathleen A.} and Pillen, {Todd J.} and Shaw, {Byers W.}",
year = "1992",
month = "5",
day = "1",
doi = "10.1007/BF01296422",
language = "English (US)",
volume = "37",
pages = "673--688",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Cytomegalovirus infection and disease after liver transplantation - An overview

AU - Stratta, Robert J.

AU - Shaeffer, Mark S.

AU - Markin, Rodney S.

AU - Wood, R. Patrick

AU - Langnas, Alan N.

AU - Reed, Elizabeth C.

AU - Donovan, Jeremiah P.

AU - Woods, Gail L.

AU - Bradshaw, Kathleen A.

AU - Pillen, Todd J.

AU - Shaw, Byers W.

PY - 1992/5/1

Y1 - 1992/5/1

N2 - Cytomegalovirus is the single most important pathogen in clinical transplantation. Although much progress has been made in our understanding of the molecular biology and epidemiology of CMV infection and in our ability to diagnosis and treat CMV disease, it remains a major cause of morbidity but is no longer a major cause of mortality after liver transplantation. Risk factors for CMV disease after liver transplantation include donor and recipient serologic status, the use of antilymphocyte therapy, and retransplantation. CMV disease occurs early after transplantation, and the most frequent site of disease is the hepatic allograft. We have treated 79 patients with intravenous ganciclovir, with ultimate control of disease achieved in 69 patients (87.3%). Preliminary results using intravenous immunoglobulin and oral acyclovir for CMV prophylaxis in high-risk patients have been encouraging. In addition to producing clinical syndromes, CMV may have direct immunologic effects and is a marker of the net state of immunosuppression.

AB - Cytomegalovirus is the single most important pathogen in clinical transplantation. Although much progress has been made in our understanding of the molecular biology and epidemiology of CMV infection and in our ability to diagnosis and treat CMV disease, it remains a major cause of morbidity but is no longer a major cause of mortality after liver transplantation. Risk factors for CMV disease after liver transplantation include donor and recipient serologic status, the use of antilymphocyte therapy, and retransplantation. CMV disease occurs early after transplantation, and the most frequent site of disease is the hepatic allograft. We have treated 79 patients with intravenous ganciclovir, with ultimate control of disease achieved in 69 patients (87.3%). Preliminary results using intravenous immunoglobulin and oral acyclovir for CMV prophylaxis in high-risk patients have been encouraging. In addition to producing clinical syndromes, CMV may have direct immunologic effects and is a marker of the net state of immunosuppression.

KW - OKT3

KW - acyclovir

KW - cytomegalovirus

KW - ganciclovir

KW - immunoglobulin

KW - immunosuppression

KW - liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=0026590468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026590468&partnerID=8YFLogxK

U2 - 10.1007/BF01296422

DO - 10.1007/BF01296422

M3 - Review article

C2 - 1314159

AN - SCOPUS:0026590468

VL - 37

SP - 673

EP - 688

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -